ERKNet Reference Center


Newcastle, Royal Victoria Infirmary


National Renal Complement Therapeutics Centre


The National Renal Complement Therapeutics Centre (NRCTC) ( is a combined clinical, diagnostic, treatment and research centre for the complement mediated diseases: atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G). It was commissioned by the National Health Service, to manage all patients in England treated with Eculizumab for these diseases (catchment area 53 million). Our service delivers this fully integrated care pathway to expedite optimal management of patients with aHUS and C3G on a shared-care basis with the referring clinicians. The NRCTC is based at the Royal Victoria Infirmary (RVI) which is part of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Our multidisciplinary team is solely dedicated to the treatment of these rare diseases. It is comprised of five consultant nephrologists (3 adult and 2 paediatric), three nurse specialists, and to provide cutting edge diagnostics, six dedicated clinical scientists working across genetics, haematology and immunology. In addition we have a state of the art clinical trial centre which allows the NRCTC to lead clinical trials. The Newcastle University complement research group comprises 7 principal investigators researching complement in renal and retinal diseases and is fully integrated with the NRCTC to provide rapid translational benefits to patients.


Senior clinician experts

Neil Sheerin   (HCP Deputy Lead)  [e-mail]

Disease expertise

» Thrombotic microangiopathies


David Kavanagh
Telephone: 44 (0) 191 282 0385
Fax: 44 (0) 191-282-0798


» National Renal Complement Therapeutics Centre

« Back to reference centers list

European Reference Networks
ERKNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission.
For more information about the ERNs and the EU health strategy, please visit